Wegovy and the laboratory: how semaglutide is developed, tested and brought to the UK

You're staring at the pen and wondering what's actually inside it

Semaglutide started as a question in a laboratory: could scientists take GLP-1, a hormone your gut releases after eating to slow digestion and reduce appetite, and engineer a version that stays active long enough to be useful as a medicine? The natural molecule breaks down within minutes. Novo Nordisk's chemists solved this by attaching a fatty acid chain to the peptide backbone, which binds semaglutide loosely to albumin proteins in the blood. That binding slows clearance dramatically. One weekly injection maintains a stable concentration in the body throughout the week, the same pharmacological principle that underpins why, for many people, appetite feels quieter on Wegovy rather than only suppressed briefly after a dose.

The semaglutide in each Wegovy pen is manufactured through a process of fermentation and chemical synthesis, purified to pharmaceutical grade, and formulated with stabilising excipients before being filled into the pre-set, pre-loaded injection devices. Storage matters because the molecule is sensitive to temperature. The guidance on storing Wegovy correctly traces back to stability data generated in the laboratory: the manufacturer's recommended refrigeration conditions exist because testing showed what happens when those conditions are not met. The Wegovy pen has a limited window at room temperature; your Patient Information Leaflet carries the exact figures.

What the clinical trials actually tested, and what the results showed

Laboratory synthesis is only the beginning. Before any regulatory body grants a weight-management licence, a medicine must pass through staged clinical evaluation. For semaglutide at the 2.4 mg dose, that evaluation is documented in the STEP programme. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight plus at least one weight-related condition over 68 weeks. Participants receiving semaglutide 2.4 mg alongside lifestyle changes lost an average of around 15% of their body weight; those on placebo lost roughly 2.4%.

A misconception worth setting down gently: some people assume large weight-loss trials are short marketing exercises. STEP 1 ran for more than a year, with structured diet and activity support, randomisation, placebo controls and a pre-specified primary endpoint. That's the standard the MHRA expects before a licence is granted. The trials also generated the safety data that informed the product's side-effect profile and the contraindications listed in the prescribing information.

The evidence picture expanded further with the 7.2 mg dose approved by the MHRA in early 2026, with trial data reporting around 20.7% average weight loss at that maintenance level. You can read more about semaglutide's broader licensed indications on our semaglutide overview page.

How regulators in the UK reviewed and licensed Wegovy

In the UK it is the MHRA, not the European Medicines Agency, that holds authority over marketing authorisations following the end of the EU regulatory alignment period. The MHRA assessed the full dossier of laboratory, preclinical and clinical data Novo Nordisk submitted for Wegovy. That review covers manufacturing quality, efficacy data and the safety profile, and results in the Summary of Product Characteristics (SmPC), the technical document that governs how the medicine can be prescribed and what information prescribers receive.

NICE then conducts its own appraisal to decide whether the NHS should fund the medicine. Its guidance on semaglutide for weight management, NICE technology appraisal TA875, sets the criteria for NHS access, including requirements around BMI, weight-related comorbidities and specialist service involvement. Private prescribing follows the licensed indications in the SmPC rather than the NHS-funding criteria, which is why some people who do not meet NHS thresholds may still be clinically suitable for treatment through a regulated private provider, and our page on how off-label Wegovy prescribing works explains the clinical and regulatory context in more detail.

If you are weighing up whether private treatment could be right for you, our page on the cost of Wegovy in the UK sets out what to expect from pricing and what a legitimate prescription service includes.

What Black Triangle status means for you as a patient

The ▼ symbol on Wegovy's packaging is not a warning sign about quality or danger. It signals that the MHRA is still actively collecting post-marketing safety data on this medicine. Black Triangle status is standard for newer medicines and typically lasts around five years after first approval. During that period, healthcare professionals and patients are particularly encouraged to report any suspected side effects, even ones that may seem minor or unrelated.

Reporting is straightforward through the MHRA Yellow Card scheme. The scheme is how real-world data feeds back into the regulatory system, complementing the controlled conditions of clinical trials. It is also one of the ways the MHRA issues updates; for example, a January 2026 Drug Safety Update reminded prescribers and patients to seek urgent medical help for severe, persistent stomach pain that may reach into the back, as this can be a sign of acute pancreatitis, which is an infrequent but serious side effect associated with GLP-1 medicines.

Our Wegovy treatment page covers the full side-effect profile in plain language, and if you'd find it helpful to hear how others have found the process, our collection of Wegovy stories from real patients gives an honest picture of what treatment can look like in practice. If you have questions about your specific health history and whether Wegovy could be suitable, the right place to start is a clinical consultation with a prescriber who can review your full picture. At nume, a real clinician reads every consultation, not software. You can start your free consultation here if you'd like to find out more.